A5015213436- Nausea and vomiting management
- Pathogenesis and Treatment of Hiccups
- Chemotherapy-induced organ toxicity mitigation
- Anesthesia and Pain Management
- Neutropenia and Cancer Infections
- Cancer survivorship and care
- Lung Cancer Treatments and Mutations
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Chemotherapy-related skin toxicity
- Advanced Breast Cancer Therapies
- Pharmacy and Medical Practices
- Sympathectomy and Hyperhidrosis Treatments
- Complementary and Alternative Medicine Studies
- Cancer Risks and Factors
- Nosocomial Infections in ICU
- Crystallization and Solubility Studies
- Pharmaceutical Practices and Patient Outcomes
- Lung Cancer Research Studies
- Safe Handling of Antineoplastic Drugs
- Sepsis Diagnosis and Treatment
- Respiratory Support and Mechanisms
- Multiple and Secondary Primary Cancers
- Vestibular and auditory disorders
- Cancer Diagnosis and Treatment
National Cancer Center Hospital East
2013-2021
ORCID
2020
National Hospital Organization Hokkaido Medical Center
2011
American Society for Gastrointestinal Endoscopy
2011
University of Tsukuba
2007
Nayoro City General Hospital
1997
Chemotherapy-induced neutropenia (CIN) has been associated with a risk of infections and chemotherapy dose reductions delays. The regimen remains one the primary determinants neutropenia, some regimens being more myelotoxic than others. Although number clinical trials have currently highlighted CIN each regimen, only few ones comprehensively examined all chemotherapeutic agents. Therefore, this study aimed to investigate factors characteristics caused by neoplastic agent using data from...
9621 Background: Standard antiemetic care for preventing CINV due to HEC is a combination of 5-HT 3 receptor antagonist (RA), DEX, and APR. This study compared the efficacy two drugs, PALO GRA, in triplet regimen. Methods: Pts with malignant solid tumor who were receiving containing 50 mg/m 2 or more CDDP enrolled. They randomly assigned either Arm A (PALO 0.75 mg, i.v.) B (GRA 1 i.v.), 30 min before chemotherapy on day 1, both arms DEX (9.9 mg 6.6 2-4, APR (125 80 2–3, p.o.). Primary...
Irinotecan (CPT-11) is widely used for the treatment of unresectable colorectal cancer in combination with fluoropyrimidines, such as 5-fluorouracil and S-1. Diarrhea one adverse effects associated CPT-11 frequently reported by patients treated CPT-11-containing regimens combined oral fluoropyrimidines. However, mechanisms involved this process, well whether fluctuations frequency differences onset time diarrhea each regimen are caused drug interactions remain unclear. Therefore, we examined...
Measuring cancer prevalence in Japan has been difficult because population-based registries have conducted limited areas. The purpose of this study was to estimate from 1995 2020 for 5-year periods based on selected registry data. 1-, 2–3-, 4–5- and partial were estimated using incidence survival Incidence calculated data registries. We the by age group, primary site, sex mixture cure fraction model. Kaplan–Meier estimates applied subgroups which did not converge projected that 1-year all...
We conducted an economic assessment using test data from the phase III TRIPLE study, which examined efficacy of a 5-hydroxytryptamine 3 receptor antagonist as part standard triplet antiemetic regimen including aprepitant and dexamethasone in preventing chemotherapy-induced nausea vomiting patients receiving cisplatin-based highly emetogenic chemotherapy (HEC).We retrospectively investigated all medicines prescribed for purposes within 120 h after initiation cisplatin administration during...
Background/Aim: The incidence of delayed chemotherapy-induced nausea and vomiting (CINV), especially nausea, in gynecologic cancer patients who receive paclitaxel carboplatin (TC) chemotherapy is unclear. We assessed risk factors for CINV these patients, examined whether it was controlled with combination antiemetic therapy. Materials Methods: Data were pooled from two prospective studies, compared between the prophylaxis groups using inverse probability treatment weighted (IPTW) analysis....
Abstract Background Of patients receiving moderate emetic risk chemotherapy (MEC), 30–90% experience chemotherapy-induced nausea and vomiting (CINV); however, the optimal antiemetic treatment remains controversial. Methods In this multicenter, prospective, observational study of adults treated with MEC while for various cancer types in Japan, enrolled kept diaries documenting CINV. All participants received a 5-hydroxytryptamine-3 receptor antagonist dexamethasone. Results 400 from May 2013...
The present study assessed the safety of outpatient oral anticancer chemotherapeutic drugs by investigating type and frequency serious adverse effects (SAEs). Emergency hospitalization, unplanned consultations telephone calls were investigated in 1,832 patients who received drug treatment at National Cancer Center Hospital East between December 1, 2014 November 30, 2015. Oral cytotoxic molecular targeted administrated to 1,140 (62.2%) 692 (37.8%) patients, respectively. A total 52 (2.8%)...
Febrile neutropenia (FN) is a critical condition in outpatient docetaxel chemotherapy. Many studies have provided evidence for the benefit of oral antibiotics low risk FN patients and December 2007, National Cancer Center Hospital East started to use routinely initial management such patients. However, it unclear whether are being taken properly as treatment chemotherapy setting. In this study using patient records, we retrospectively investigated adherence who had been prescribed needed...
Abstract Background Among patients with colorectal cancer (CRC) treated oxaliplatin (L-OHP)-based chemotherapy, delayed chemotherapy-induced nausea and vomiting (CINV) have not been well controlled. Methods We pooled data from two prospective observational studies in Japan one phase III clinical trial to assess whether CINV could be controlled a combination of three antiemetics adding neurokinin-1 receptor antagonist identified individual risk factors, using an inverse probability...
As hypoalbuminemia is a risk factor of severe hematological toxicity occurring in anticancer chemotherapy,we examined serum albumin levels outpatients receiving several different chemotherapy regimens.The data 4215 samples collected from 946 were investigated.Mean (±SD) was 3.8±0.4 g/dL with the 2.0-2.9 g/dL,3.0-3.9 and 4.0-4.9 accounting for 2.5%,56.6% 40.9% total number samples,respectively.Serum differed by disease regimen.The mean each regimen significantly directly correlated hematocrit...
Background/Aim: Recently, the number of patients with cancer receiving outpatient chemotherapy using oral anticancer drugs has increased, but currently available is not safer than that before. The present study aimed to identify risk factors associated unplanned acute care (UAC) requiring chemotherapy-related consultation and hospitalisation. Patients Methods: We conducted a case– control among 1,674 who received drug treatment either alone or in combination injectable at National Cancer...
Abstract Background: Of patients receiving moderate emetic risk chemotherapy (MEC), 30%–90% experience chemotherapy-induced nausea and vomiting (CINV); however, the optimal antiemetic treatment remains controversial. Methods: In this multicenter, prospective, observational study of adults treated with MEC while for various cancer types in Japan, enrolled kept diaries documenting CINV. All participants received a 5-hydroxytryptamine-3 receptor antagonist dexamethasone. Results: 400 from May...
Aprepitant is a neurokinin-1 (NK1) receptor antagonist that has been shown to improve the control of chemotherapyinduced nausea and vomiting. administered for 3 days with 5-HT3 dexamethasone patients receiving highly emetogenic chemotherapy as antiemetic prophylaxis according guidelines American Society Clinical Oncology (ASCO), National Comprehensive Cancer Network (NCCN), Japanese used in Center Hospital East. In phase II clinical trial, effectiveness aprepitant was certified by 5-day...
A 43-year-old female with steroid-responsive sensorineural hearing loss (SNHL) was described. She had been treated steroids for idiopathic thrombocytopenic purpura (ITP) since 1981.The patient complained of sudden and tinnitus in the left ear on 9th June, 1995, at which time, 2.5mg prednisolone administered ITP. The audiogram showed SNHL low frequency sounds. Immunological studies positive rheumatoid factor antinuclear antibody, high levels complement, immune complex, IgG IgA.The patient's...